Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730821 · ClinicalTrials.gov registry record · Phase 1
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT00730821 is a Phase 1 study of Neoplasms that has completed, run by Boehringer Ingelheim. The registered enrollment target is 28 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00730821, a Phase 1 study of Neoplasms, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule. Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and BIBW 2992, and if data allow the determination of the pharmacokinetic influence of BIBW 2992 on BIBF 1120 and vice versa.
Conditions Studied
Interventions
- DRUG BIBW 2992
- DRUG BIBF 1120
Study Locations (4)
Arizona
- 1239.1.3 Boehringer Ingelheim Investigational Site - Scottsdale
Florida
- 1239.1.1 Boehringer Ingelheim Investigational Site - Tampa
Michigan
- 1239.1.2 Boehringer Ingelheim Investigational Site - Detroit
Nebraska
- 1239.1.4 Boehringer Ingelheim Investigational Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730821
The ClinicalTrials.gov registry entry for NCT00730821 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which BIBW 2992 is the first listed.
NCT00730821 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT00730821 about?
NCT00730821 is a clinical study titled "Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors". The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule. Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and B...
What is the current status of trial NCT00730821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2007-01.
What conditions does trial NCT00730821 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00730821?
The interventions under investigation include: BIBW 2992 (DRUG), BIBF 1120 (DRUG).
Who is sponsoring clinical trial NCT00730821?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00730821 being conducted?
This trial has 4 study locations across Arizona, Florida, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.